Abstract
The results of several cross-sectional trials suggest that patients with rheumatoid arthritis (RA) have increased vascular risk and cardiovascular mortality. It was demonstrated that inflammation plays a pivotal role in the pathogenesis of both RA and atherosclerosis. This association may explain the high incidence of cardiovascular disease in RA patients. A number of recent studies show that routine statin use in patients with RA offers considerable advantages. Statin treatment has been supported to exert a beneficial effect on disease activity, swollen joint count, endothelial dysfunction, and arterial stiffness in RA patients. These improvements are coupled with a mild to moderate improvement in plasma markers of inflammation, such as C-reactive protein and erythrocyte sedimentation rate. Statins have a satisfactory safety profile with relatively few adverse effects. In the absence of side effects and contraindications, it may be reasonable to consider statin use in selected cases, particularly in patients with a long history of active RA who are at increased cardiovascular risk.
Similar content being viewed by others
References
Walker JG, Littlejohn GO (2006) Measuring quality of life in rheumatic conditions. Clin Rheumatol 26:671–673
Palkonyai E, Kolarz G, Kopp M et al (2007) Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study. Clin Rheumatol 26:753–758
Isik A, Koca SS, Ozturk A, Mermi O (2007) Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol 26:872–878
Birtane M, Uzunca K, Tastekin N, Tuna H (2007) The evaluation of quality of life in fibromyalgia syndrome: a comparison with rheumatoid arthritis using SF-36 Health Survey. Clin Rheumatol 26:679–684
Taal E, Bobietinska E, Lloyd J (2006) Successfully living with chronic arthritis. The role of the allied health professionals. Clin Rheumatol 25:189–197
Brooks PM (2006) The burden of musculoskeletal disease—a global perspective. Clin Rheumatol 25:778–781
Frostegard J (2005) Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 25:1776–1785
Sherer Y, Shoenfeld Y (2006) Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2:99–106
Chung CP, Avalos I, Raggi P, Stein CM (2007) Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 26:1228–1233
Van Doornum S, McColl G, Wicks IP (2002) Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873
Van Doornum S, McColl G, Jenkins A et al (2003) Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 48:72–80
Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8–17
Giles JT, Post W, Blumenthal RS et al (2006) Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2:320–329
Warrington KJ, Kent PD, Frye RL et al (2005) Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 7:R984–R991
Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30:1196–1202
Gazi IF, Boumpas DT, Mikhailidis DP, Ganotakis ES (2007) Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 25:102–111
Costenbader KH, Coblyn JS (2005) Statin therapy in rheumatoid arthritis. South Med J 98:534–540
Arnaud C, Mach F (2006) Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 54:390–392
Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126
Binder CJ, Chang MK, Shaw PX et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218–1226
Hansson GK, Holm J, Jonasson L (1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 135:169–175
Frostegard J, Ulfgren AK, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33–43
Wick G, Knoflach M, Xu Q (2004) Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 22:361–403
Xu Q, Dietrich H, Steiner HJ et al (1992) Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 12:789–799
George J, Harats D, Gilburd B et al (2000) Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102:1822–1827
George J, Afek A, Gilburd B et al (1998) Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98:1108–1115
Mach F, Schonbeck U, Sukhova GK et al (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394:200–203
Toubi E, Shoenfeld Y (2004) The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 37:457–464
Nicoletti A, Kaveri S, Caligiuri G et al (1998) Immunoglobulin treatment reduces atherosclerosis in Apo E knockout mice. J Clin Invest 102:910–918
Robertson AK, Rudling M, Zhou X et al (2003) Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 112:1342–1350
Solomon DH, Karlson EW, Rimm EB et al (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303–1307
Arthritis Research Campaign. Arthritis: the big picture. http://www.arc.org.uk/arthinfo/bigpic.asp#6. Accessed 4 November 2007
Davenport G; Primary Care Rheumatology Society Steering Committee (2004) Rheumatology and musculoskeletal medicine. Br J Gen Pract 54:457–464
Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481–494
Nicola PJ, Maradit-Kremers H, Roger VL et al (2005) The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52:412–420
Snow MH, Mikuls TR (2005) Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 17:234–241
Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52:402–411
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24:445–451
del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737–2745
Jacobsson LT, Turesson C, Hanson RL et al (2001) Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum 44:1170–1176
Chung CP, Oeser A, Raggi P et al (2005) Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 52:3045–3053
Park YB, Ahn CW, Choi HK et al (2003) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 46:1714–1719
Kumeda Y, Inaba M, Goto H et al (2002) Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 46:1489–1497
Daza L, Aguirre M, Jimenez M et al (2007) Common carotid intima-media thickness and von Willebrand factor serum levels in rheumatoid arthritis female patients without cardiovascular risk factors. Clin Rheumatol 26:533–537
Nagata-Sakurai M, Inaba M, Goto H et al (2003) Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 48:3061–3067
Roman MJ, Moeller E, Davis A et al (2006) Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 144:249–256
Dessein PH, Joffe BI (2006) When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol 33:201–203
Cederholm A, Svenungsson E, Jensen-Urstad K et al (2005) Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203
Swanberg M, Lidman O, Padyukov L et al (2005) MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 37:486–494
Abeles AM, Pillinger MH (2006) Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy. Arthritis Rheum 54:393–407
Tristano AG, Fuller K (2006) Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immunopharmacol 6:1833–1846
Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26:201–204
Turesson C (2004) Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Des 10:129–143
Palinski W, Napoli C (2002) Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 22:1745–1750
Choi M, Rolle S, Rane M et al (2003) Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA. Kidney Int 63:96–106
Sadeghi MM, Tiglio A, Sadigh K et al (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71:1262–1268
Kwak B, Mulhaupt F, Veillard N et al (2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 131:41–46
Dolhain RJ, van der Heiden AN, ter Haar NT et al (1996) Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 39:1961–1969
Nagashima T, Okazaki H, Yudoh K et al (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586
McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021
Hermann F, Forster A, Chenevard R et al (2005) Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 45:461–464
Ridker PM, Cushman M, Stampfer MJ et al (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973–979
Ridker PM, Buring JE, Shih J et al (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733
Koenig W, Sund M, Frohlich M et al (1999) C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237–242
Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565
Pham T, Gossec L, Constantin A et al (2006) Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Jt Bone Spine 73:379–387
McInnes IB, McCarey DW, Sattar N (2004) Do statins offer therapeutic potential in inflammatory arthritis. Ann Rheum Dis 63:1535–1537
Sattar N, McInnes IB (2005) Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 17:286–292
Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2:205–207
Klareskog L, Hamsten A (2004) Statins in rheumatoid arthritis—two birds with one stone. Lancet 363:2011–2012
Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423–1427
Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116:408–416
Kanda H, Hamasaki K, Kubo K et al (2002) Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 29:2024–2026
Abud-Mendoza C, de la Fuente H, Cuevas-Orta E et al (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611
Van Doornum S, McColl G, Wicks IP (2004) Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 63:1571–1575
Maki-Petaja KM, Booth AD, Hall FC et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50:852–858
Okamoto H, Koizumi K, Kamitsuji S et al (2007) Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 34:964–968
Tikiz C, Utuk O, Pirildar T et al (2005) Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 32:2095–2101
Charles-Schoeman C, Khanna D, Furst DE et al (2007) Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 34:1459–1464
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Paraskevas, K.I. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27, 281–287 (2008). https://doi.org/10.1007/s10067-007-0806-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0806-8